BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36855266)

  • 1. Resistance prediction in high-grade serous ovarian carcinoma with neoadjuvant chemotherapy using data-independent acquisition proteomics and an ovary-specific spectral library.
    Qian L; Zhu J; Xue Z; Gong T; Xiang N; Yue L; Cai X; Gong W; Wang J; Sun R; Jiang W; Ge W; Wang H; Zheng Z; Wu Q; Zhu Y; Guo T
    Mol Oncol; 2023 Aug; 17(8):1567-1580. PubMed ID: 36855266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
    Luo Y; Lee M; Kim HS; Chung HH; Song YS
    Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
    Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
    Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
    J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.
    Fagö-Olsen CL; Ottesen B; Kehlet H; Antonsen SL; Christensen IJ; Markauskas A; Mosgaard BJ; Ottosen C; Soegaard CH; Soegaard-Andersen E; Hoegdall C
    Gynecol Oncol; 2014 Feb; 132(2):292-8. PubMed ID: 24321400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
    Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study.
    Gao Y; Li Y; Zhang C; Han J; Liang H; Zhang K; Guo H
    J Ovarian Res; 2019 Sep; 12(1):85. PubMed ID: 31519183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
    Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
    Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
    Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
    Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
    Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?
    Himoto Y; Cybulska P; Shitano F; Sala E; Zheng J; Capanu M; Nougaret S; Nikolovski I; Vargas HA; Wang W; Mueller JJ; Chi DS; Lakhman Y
    Gynecol Oncol; 2019 Nov; 155(2):192-200. PubMed ID: 31521322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
    Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
    Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal Evolution of
    Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
    Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.